KNSA FY 2024 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$423M+56.6% YoY

Gross Profit

$362M85.6% margin

Operating Income

-$46M-10.8% margin

Net Income

-$43M-10.2% margin

EPS (Diluted)

$-0.60

Cash Flow

Operating Cash Flow

$26M

Free Cash Flow

$25M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$581M

Total Liabilities

$142M

Stockholders' Equity

$438M

Cash & Equivalents

$184M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$423M	$270M	+56.6%
Gross Profit	$362M	$214M	+69.5%
Operating Income	-$46M	-$25M	-81.0%
Net Income	-$43M	$14M	-406.7%